The EU has agreed major expansions of its deals with the COVID-19 vaccine makers Pfizer/BioNTech and Moderna, adding a further 350 million vaccine doses to its confirmed orders.
Pfizer And Moderna Reap Rewards Of Expanded US And EU Deals
Hundreds Of Millions More Doses Purchased
The two rival mRNA vaccines are proving attractive in the face of new variants, and could dominate once SARS-CoV2 enters the ‘endemic’ stage.
More from Business
More from Scrip
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.
• By
Compass' bispecific antibody tovecimig hits primary efficacy endpoint in Phase II/III top-line data in advanced biliary tract cancer, and may have class side-effect advantages. But additional survival data may be needed to support US approval.
• By
AstraZeneca remains committed to investing in R&D and alliances in China, where Susan Galbraith, the UK major’s head of oncology R&D, sees innovation eventually reaching parity with the US and Europe.